Fig 2.

BRCAness profile distinguishes between platinum-sensitive and platinum-resistant tumor biopsy specimens in patients with known BRCA germline mutation status. (A) Hierarchical clustering that is based on the expression pattern of the 60 genes of the BRCAness profile distinguished between platinum-resistant and platinum-sensitive tumor biopsy samples. Platinum sensitivity was defined as a complete response to treatment maintained without progression for at least 6 months after platinum therapy. Platinum resistance was defined as progressive disease on platinum therapy, or less than a complete response to platinum therapy, or progression within 6 months of completing platinum therapy. (B) Correlation of BRCAness profile with platinum sensitivity and BRCA germline mutation status. The BRCAness profile accurately distinguished between platinum sensitivity and platinum resistance in eight of 10 tumor specimens, which in turn correlated with the presence of mutated versus functional BRCA gene status, respectively. NBL, non–BRCA-like; BL, BRCA-like.